Fully Enrolled Confirmatory Studies Can De-Risk Novel Accelerated Approval Endpoints – FDA Official

Oncology Center of Excellence Deputy Director Paul Kluetz talks about what might make a drug a good candidate for a Project Frontrunner-type development program and how sponsors might benefit from FDA’s experience with OCE’s first Project Pragmatica pilot.